We concluded the year on a strong note, with Q4 FY26 marking our highest-ever quarterly revenue and EBITDA performance. All our business segments, HPPC, TSC and AHN, delivered healthy double-digit growth during the quarter, reflecting the strength of our diversified portfolio and our ability to execute well across end-user industries. Our diversified portfolio and balanced presence across end-user industries helped us navigate a mixed operating environment, including volatility arising from the ongoing geopolitical conflict, while sustaining growth. Margins during the quarter were impacted by the prevailing raw material situation and the lag in passing on cost inflation. We remain focused on calibrated pricing actions, improving product mix and driving operating leverage, which should support margin recovery over time. We continue to strengthen our manufacturing base in a calibrated manner. During the quarter, Unitop commissioned the remaining 15,000 MTPA ethoxylation capacity at Dahej, taking total installed ethoxylation capacity to 66,000 MTPA. Our earlier capex plans announced in April 2025, have been rephased over the next two years to align with evolving business requirements and market conditions, while maintaining the overall strategic intent. As we look ahead, our focus remains on disciplined execution, customer-led innovation and profitable growth. With strong R&D capabilities, expanding capacities, a healthy balance sheet and sharper strategic alignment across businesses, we are well placed to build an integrated, intelligent and impactful specialty chemicals platform and deliver sustained value for all our stakeholders.